Skip to main content

Circulating Biomarkers, Exosomes & Liquid Biopsy Europe 2019

Our team is excited to interact with experts from across the world and share the potential of urine as a liquid biopsy, especially in the field of oncology. We will also be showcasing Colli-Pee, our innovative urine capturing device, and the latest variants for collection of small and large volumes of urine.

Come find us to learn more about the potential applications.

Disclaimer

Novosanis is a wholly owned subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology. The Colli-Pee® family, the heart of the company, allows volumetric and standardized collection of first-void urine. The platform consists of variants capturing a range of urine volumes for different application purposes. Urine collection through the Colli-Pee® device is easy, comfortable, and more accurate than a regular urine cup. First-void urine has shown to improve detection of infectious diseases, including sexually transmitted infections as well as for some cancers applications. The Colli-Pee® device enables immediate mixing of the first-void urine sample with a preservative, improving stability of the urine specimen. Novosanis markets its products worldwide and has a global customer base.